Keyphrases
Eosinophils
100%
Acute Exacerbation of COPD (AECOPD)
100%
Non-inferiority Trial
100%
Corticosteroid Therapy
100%
Systemic Corticosteroids
77%
Prednisolone
33%
Corticosteroid Exposure
33%
Treatment Duration
22%
Treatment Failure
22%
Eosinophil Count
22%
Number of Days
22%
Guided Therapy
22%
Blood Eosinophil Count
22%
Denmark
11%
Adverse Effects
11%
Patients Included
11%
Pharmacological Treatment
11%
Between-group Difference
11%
Intention-to-treat Analysis
11%
Intention-to-treat
11%
Admission to Hospital
11%
Methylprednisolone
11%
Safety Profile
11%
Group Differences
11%
Absolute Difference
11%
First Day
11%
Forced Expiratory Volume in 1 Second (FEV1)
11%
Oral Tablets
11%
Chronic Obstructive Pulmonary Disease
11%
Number of Deaths
11%
Airflow Limitation
11%
Respiratory Medicine
11%
Last Observation Carried Forward
11%
Forced Vital Capacity
11%
Post-bronchodilator
11%
Noninferiority Margin
11%
Group Assignment
11%
Respiratory Department
11%
Capacity Ratio
11%
Emergency Room Visits
11%
Systemic Corticosteroid Therapy
11%
University-affiliated
11%
Personalized Biomarkers
11%
Affiliated Hospitals
11%
Medicine and Dentistry
Disease Exacerbation
100%
Chronic Obstructive Pulmonary Disease
100%
Eosinophil
100%
Corticosteroid Therapy
100%
Noninferiority Trial
100%
Corticosteroid
53%
Prednisolone
23%
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
23%
Intention-to-Treat Analysis
15%
Drug Therapy
7%
Adverse Event
7%
Biological Marker
7%
Recurrent Disease
7%
Treatment Duration
7%
Forced Expiratory Volume
7%
Methylprednisolone
7%
Airflow
7%
Respiratory Medicine
7%
Forced Vital Capacity
7%
Bronchodilating Agent
7%
Pharmacology, Toxicology and Pharmaceutical Science
Disease Exacerbation
100%
Chronic Obstructive Lung Disease
100%
Corticosteroid
100%
Noninferiority Trial
100%
Prednisolone
37%
Tablet
25%
Adverse Event
12%
Biological Marker
12%
Recurrent Disease
12%
Methylprednisolone
12%
Bronchodilating Agent
12%
Immunology and Microbiology
Eosinophil
100%
Eosinophil Count
44%
Prednisolone
33%
Methylprednisolone
11%
Forced Expiratory Volume
11%
Airflow
11%
Bronchodilator
11%
Forced Vital Capacity
11%